IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up on Analyst Upgrade

IDEAYA Biosciences, Inc. (NASDAQ:IDYAGet Free Report)’s share price gapped up before the market opened on Monday after BTIG Research raised their price target on the stock from $55.00 to $62.00. The stock had previously closed at $34.26, but opened at $39.28. BTIG Research currently has a buy rating on the stock. IDEAYA Biosciences shares last traded at $37.73, with a volume of 858,095 shares changing hands.

IDYA has been the subject of a number of other reports. Oppenheimer upped their price target on shares of IDEAYA Biosciences from $53.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday. Wedbush reaffirmed an “outperform” rating and issued a $56.00 price target (up from $52.00) on shares of IDEAYA Biosciences in a research note on Monday. Mizuho initiated coverage on shares of IDEAYA Biosciences in a research note on Monday. They issued an “outperform” rating and a $50.00 price target for the company. Citigroup upped their price target on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, March 21st. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $63.00 target price on shares of IDEAYA Biosciences in a report on Monday. Fourteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $51.42.

Get Our Latest Analysis on IDEAYA Biosciences

Insider Buying and Selling at IDEAYA Biosciences

In other IDEAYA Biosciences news, insider Michael Anthony White sold 28,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $36.24, for a total value of $1,032,840.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other IDEAYA Biosciences news, insider Michael Anthony White sold 28,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $36.24, for a total value of $1,032,840.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Yujiro S. Hata sold 56,711 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $41.61, for a total transaction of $2,359,744.71. Following the completion of the sale, the chief executive officer now directly owns 677,887 shares of the company’s stock, valued at $28,206,878.07. The disclosure for this sale can be found here. In the last quarter, insiders have sold 119,644 shares of company stock worth $4,832,228. 3.50% of the stock is currently owned by company insiders.

Institutional Trading of IDEAYA Biosciences

Several large investors have recently modified their holdings of IDYA. Covestor Ltd boosted its holdings in shares of IDEAYA Biosciences by 9,225.0% during the 1st quarter. Covestor Ltd now owns 1,119 shares of the company’s stock worth $49,000 after buying an additional 1,107 shares during the period. Comerica Bank boosted its holdings in shares of IDEAYA Biosciences by 723.5% during the 1st quarter. Comerica Bank now owns 1,507 shares of the company’s stock worth $66,000 after buying an additional 1,324 shares during the period. JTC Employer Solutions Trustee Ltd bought a new stake in shares of IDEAYA Biosciences during the 1st quarter worth $67,000. AJOVista LLC bought a new stake in shares of IDEAYA Biosciences during the 4th quarter worth $99,000. Finally, SG Americas Securities LLC bought a new stake in shares of IDEAYA Biosciences during the 1st quarter worth $101,000. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Trading Down 2.3 %

The company’s fifty day moving average is $38.44 and its 200-day moving average is $40.74. The firm has a market capitalization of $2.92 billion, a P/E ratio of -19.21 and a beta of 0.86.

IDEAYA Biosciences (NASDAQ:IDYAGet Free Report) last released its earnings results on Tuesday, May 7th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.09%. The business’s quarterly revenue was down 100.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.49) EPS. On average, equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -2.37 EPS for the current year.

About IDEAYA Biosciences

(Get Free Report)

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

Featured Stories

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.